NO20083576L - Peptider av regulatoriske eller hjelpeproteiner av HIV, samt sammensetninger og anvendelser derav - Google Patents

Peptider av regulatoriske eller hjelpeproteiner av HIV, samt sammensetninger og anvendelser derav

Info

Publication number
NO20083576L
NO20083576L NO20083576A NO20083576A NO20083576L NO 20083576 L NO20083576 L NO 20083576L NO 20083576 A NO20083576 A NO 20083576A NO 20083576 A NO20083576 A NO 20083576A NO 20083576 L NO20083576 L NO 20083576L
Authority
NO
Norway
Prior art keywords
seq
polypeptide
hiv
regulatory
peptides
Prior art date
Application number
NO20083576A
Other languages
English (en)
Norwegian (no)
Inventor
Alan Gregory Stoloff
Romero Wilson Caparros-Wanderley
Original Assignee
Peptcell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0604920A external-priority patent/GB0604920D0/en
Priority claimed from GB0614260A external-priority patent/GB0614260D0/en
Application filed by Peptcell Ltd filed Critical Peptcell Ltd
Publication of NO20083576L publication Critical patent/NO20083576L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • C07K14/15Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16HIV-1 ; HIV-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55544Bacterial toxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16071Demonstrated in vivo effect
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16211Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16311Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16311Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20083576A 2006-03-10 2008-08-18 Peptider av regulatoriske eller hjelpeproteiner av HIV, samt sammensetninger og anvendelser derav NO20083576L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0604920A GB0604920D0 (en) 2006-03-10 2006-03-10 Peptide sequences and compositions
GB0614260A GB0614260D0 (en) 2006-07-18 2006-07-18 Peptide sequences and compositions
PCT/GB2007/000812 WO2007104932A2 (en) 2006-03-10 2007-03-09 Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof

Publications (1)

Publication Number Publication Date
NO20083576L true NO20083576L (no) 2008-12-10

Family

ID=38232608

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083576A NO20083576L (no) 2006-03-10 2008-08-18 Peptider av regulatoriske eller hjelpeproteiner av HIV, samt sammensetninger og anvendelser derav

Country Status (21)

Country Link
US (4) US20100055119A1 (ru)
EP (2) EP2392587B1 (ru)
JP (3) JP2009529570A (ru)
KR (1) KR20080106467A (ru)
CN (2) CN102443052B (ru)
AP (2) AP2015008680A0 (ru)
AU (1) AU2007226430B2 (ru)
BR (1) BRPI0708708A2 (ru)
CA (1) CA2645342A1 (ru)
DK (2) DK2392587T3 (ru)
EA (1) EA019733B1 (ru)
ES (2) ES2616341T3 (ru)
HK (1) HK1171027A1 (ru)
IL (2) IL193965A0 (ru)
MX (1) MX2008011520A (ru)
NO (1) NO20083576L (ru)
NZ (1) NZ570708A (ru)
PL (1) PL2392587T3 (ru)
SG (1) SG170092A1 (ru)
UA (1) UA97800C2 (ru)
WO (1) WO2007104932A2 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
EP3077417A1 (en) 2013-12-08 2016-10-12 Peptcell Limited Hiv antigens and antibodies and compositions, methods and uses thereof
CA3161633A1 (en) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Dosage regimens for vaccines

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330359A3 (en) 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of hiv-1 infection
DE4141970C2 (de) 1991-12-16 1998-02-19 Charite Med Fakultaet Kombinationsimpfstoff gegen AIDS, Bilharziose und Tuberkulose und Verfahren zu seiner Herstellung
CA2151283A1 (en) 1993-10-04 1995-04-20 Akiyoshi Matsumoto Polypeptide and anti-hiv agent prepared therefrom
CN1055701C (zh) 1993-10-19 2000-08-23 味之素株式会社 能诱导对hiv免疫应答的肽及含有该肽的预防、治疗aids的药物
US5843724A (en) * 1995-04-27 1998-12-01 Rutgers University Chimeric nucleic acids and proteins for inhibiting HIV-1 expression
EP0980388A1 (en) * 1997-05-20 2000-02-23 YISSUM RESEARCH DEVELOPMENT COMPANY of the Hebrew University of Jerusalem Vif-derived hiv protease inhibitors
WO1999013896A1 (en) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Attenuated vif dna immunization cassettes for genetic vaccines
US6228128B1 (en) 1997-11-10 2001-05-08 Charlotte Johansen Antimicrobial activity of laccases
US20030180314A1 (en) 1998-07-10 2003-09-25 Degroot Anne Immunogenic, cross-clade, HIV peptides
US20020182222A1 (en) * 1998-07-10 2002-12-05 Groot Anne De HIV vaccine candidate peptides
EP1155035A2 (de) * 1999-02-19 2001-11-21 Ulrich Schubert Synthetische peptide des regulatorischen virusproteins r (vpr) des humanen immundefizienzvirus typ 1 (hiv-1) und ihre verwendung
NO311807B1 (no) 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
JP4873810B2 (ja) * 1999-10-05 2012-02-08 エピミューン インコーポレイテッド ペプチドおよび核酸組成物を使用する、ヒト免疫不全ウイルス−1に対する細胞性免疫応答の誘導
CA2397998A1 (en) 2000-01-28 2001-08-02 Statens Serum Institut Hiv peptides and nucleic acids encoding them for diagnosis and control of hiv infection
NO314587B1 (no) 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
US6733994B2 (en) * 2000-10-04 2004-05-11 The Trustees Of The University Of Pennsylvania Highly expressible genes
EP1490396A4 (en) * 2001-03-01 2006-04-19 Us Gov Health & Human Serv IMMUNOGENIC HIV PEPTIDES AS REAGENTS AND AS VACCINES
US6974574B2 (en) * 2001-08-16 2005-12-13 The General Hospital Corporation Methods of inducing an HIV specific response using a Vpr-specific epitope
RU2214274C2 (ru) 2001-08-16 2003-10-20 Государственное предприятие Институт иммунологии Федерального управления медико-биологических экстремальных проблем при МЗ РФ Иммуногенная композиция, содержащая химерный полипептид вич, полипептиды и тест-система для обнаружения антител к вич
CA2357906A1 (en) 2001-09-28 2003-03-28 Institut Pasteur Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections
WO2004031345A2 (en) 2002-05-20 2004-04-15 The General Hospital Corporation Cytotoxic t-cell epitopes of hiv-1 virus
CA2500715A1 (en) 2002-10-03 2004-04-15 Epimmune, Inc. Hla binding peptides and their uses
EP1609107A4 (en) * 2003-03-28 2006-08-30 Idm Pharma Inc METHOD FOR IDENTIFYING OPTIMAL PEPTIDE PITOPARIANTS
AU2004274937B9 (en) * 2003-09-17 2011-04-14 Duke University Consensus/ancestral immunogens
US8795685B2 (en) * 2004-08-17 2014-08-05 Institut Gustave Roussy Mutated HIV Nef for modulating immunity
CN101969996A (zh) 2005-08-23 2011-02-09 加利福尼亚大学董事会 多价疫苗

Also Published As

Publication number Publication date
DK2004676T3 (en) 2017-02-20
WO2007104932A2 (en) 2007-09-20
KR20080106467A (ko) 2008-12-05
US20150182618A1 (en) 2015-07-02
SG170092A1 (en) 2011-04-29
IL219544A0 (en) 2012-06-28
ES2616341T3 (es) 2017-06-12
EP2004676A2 (en) 2008-12-24
AP2008004609A0 (en) 2008-10-31
US20130039937A1 (en) 2013-02-14
CN102443052B (zh) 2014-12-31
CN102443052A (zh) 2012-05-09
AP3642A (en) 2016-03-16
EA019733B1 (ru) 2014-05-30
JP2015007069A (ja) 2015-01-15
HK1171027A1 (en) 2013-03-15
CN104558126B (zh) 2020-02-14
US20100055119A1 (en) 2010-03-04
EP2392587B1 (en) 2016-05-04
JP2009529570A (ja) 2009-08-20
PL2392587T3 (pl) 2016-08-31
JP2013040172A (ja) 2013-02-28
MX2008011520A (es) 2009-01-07
US9675686B2 (en) 2017-06-13
EA200870342A1 (ru) 2009-02-27
WO2007104932A3 (en) 2007-11-22
AP2015008680A0 (en) 2015-08-31
EP2392587A1 (en) 2011-12-07
US20170281750A1 (en) 2017-10-05
NZ570708A (en) 2011-12-22
CA2645342A1 (en) 2007-09-20
CN104558126A (zh) 2015-04-29
US8992934B2 (en) 2015-03-31
IL193965A0 (en) 2011-08-01
DK2392587T3 (en) 2016-05-23
AU2007226430A2 (en) 2008-10-09
AU2007226430B2 (en) 2013-08-29
BRPI0708708A2 (pt) 2011-06-07
US10034933B2 (en) 2018-07-31
EP2004676B1 (en) 2016-11-16
JP6422698B2 (ja) 2018-11-14
UA97800C2 (ru) 2012-03-26
ES2573105T3 (es) 2016-06-06
AU2007226430A1 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
NO20083416L (no) Peptidsekvenser og preparater
MX2019010275A (es) Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este.
AR064642A1 (es) Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
NO20063026L (no) Antistoffer
NO20082149L (no) Hundeinfluensavirus og relaterte sammensetninger og fremgangsmater for bruk
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
PH12021550030A1 (en) Nucleotide sequences encoding peptide antigens of sars-cov-2 virus and use thereof
BRPI0412799A (pt) imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura
DE602005018615D1 (de) Schen polypeptiden und deren verwendung als impfstoffe und in der immuntherapie
ES2531115T3 (es) Combinaciones de clados de RrgB neumocócicos
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
JP2020509770A5 (ru)
JP2012516140A5 (ru)
NO20083576L (no) Peptider av regulatoriske eller hjelpeproteiner av HIV, samt sammensetninger og anvendelser derav
MX2009007261A (es) Vacuna de peptido foxp3.
BRPI0508916A (pt) polipeptìdeos hìbridos imunogênicos antiobesidade e composição de vacina antiobesidade compreendendo-os
BR0309491A (pt) Composição de vacina, composição imunogênica, utilização de uma proteìna e7 e anticorpos neutralizantes
RU2009115688A (ru) Иммуногенные гибридные полипептиды против ожирения и композиция вакцин против ожирения, содержащая эти полипептиды
NZ603854A (en) West nile virus vaccine
DK1913020T3 (da) Immunogene konstrukter
AR116876A1 (es) Vacuna de ibv 4/91 con proteína espicular heteróloga
MX2010010025A (es) Proteina de fusion con direccionamiento de antigenos vacunales a celulas presentadoras de antigeno y sus aplicaciones.
BRPI0715331B8 (pt) polipeptídeo que compreende uma porção n-terminal e uma porção c-terminal, e uso do mesmo
WO2007127290A3 (en) Method for producing viral vaccine and therapeutic peptide antigens
BR0012556A (pt) Genes e vacinas de ehrlichia canis

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application